Cite
HARVARD Citation
Volkers, A. et al. (n.d.). DOP63 Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease. Journal of Crohn's and colitis. pp. i108-i109. [Online].